Emergent BioSolutions | EBS - Debt


Emergent BioSolutions reported $903.2M in Debt for its fiscal quarter ending in June of 2023.





Debt Change Date
Acadia Pharmaceuticals USD 50.79M 1.39M Mar/2026
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
ALKERMES USD 1.58B 1.51B Mar/2026
Alnylam Pharmaceuticals USD 1.27B 5.33M Mar/2026
Amarin USD 0 0 Mar/2025
ANI Pharmaceuticals USD 617.04M 3.28M Dec/2025
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Coherus Biosciences USD 294.92M 1.25M Mar/2025
Emergent BioSolutions USD 903.2M 495.2M Jun/2023
Exelixis USD 169.54M 3.5M Mar/2026
Glaxosmithkline GBP 19.06B 1.31B Mar/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Ionis Pharmaceuticals USD 1.91B 425.5M Jun/2026
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Lexicon Pharmaceuticals USD 99.51M 243K Dec/2023
Lonza CHF 4.71B 915M Dec/2024
Merck USD 49.12B 222M Mar/2026
Moderna USD 1.3B 7M Mar/2026
Myriad Genetics USD 59.3M 19.7M Mar/2025
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Pacira USD 367.66M 4.53M Mar/2026
Pfizer USD 63.73B 231M Mar/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Sanofi EUR 23.58B 3.56B Jun/2026
Sarepta Therapeutics USD 1.04B 210.44M Dec/2025
United Therapeutics USD 200M 100M Mar/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024